These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20036961)

  • 1. Characterization of a three-drug nonlinear mixture response model.
    Brun YF; Greco WR
    Front Biosci (Schol Ed); 2010 Jan; 2(2):454-67. PubMed ID: 20036961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.
    Brun YF; Dennis CG; Greco WR; Bernacki RJ; Pera PJ; Bushey JJ; Youn RC; White DB; Segal BH
    Antimicrob Agents Chemother; 2007 May; 51(5):1804-12. PubMed ID: 17325217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
    White DB; Slocum HK; Brun Y; Wrzosek C; Greco WR
    Curr Drug Metab; 2003 Oct; 4(5):399-409. PubMed ID: 14529372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel flexible approach for evaluating fixed ratio mixtures of full and partial agonists.
    Gennings C; Carter WH; Carney EW; Charles GD; Gollapudi BB; Carchman RA
    Toxicol Sci; 2004 Jul; 80(1):134-50. PubMed ID: 15084752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible interaction model for complex interactions of multiple anesthetics.
    Fidler M; Kern SE
    Anesthesiology; 2006 Aug; 105(2):286-96. PubMed ID: 16871062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixture effects of chemicals: The difficulty to choose appropriate mathematical models for appropriate conclusions.
    Lasch A; Lichtenstein D; Marx-Stoelting P; Braeuning A; Alarcan J
    Environ Pollut; 2020 May; 260():113953. PubMed ID: 31962267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concepts of synergism and antagonism.
    Merlin JL
    Anticancer Res; 1994; 14(6A):2315-9. PubMed ID: 7825965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
    Levasseur LM; Slocum HK; Rustum YM; Greco WR
    Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
    Gupta AK; Kohli Y
    Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth.
    Ghannoum MA; Motawy MS; Abu Hatab MA; Ibrahim AS; Criddle RS
    Antimicrob Agents Chemother; 1989 May; 33(5):717-25. PubMed ID: 2665643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials.
    Kang W; DiPaola RS; Vazquez A
    BMC Med Res Methodol; 2013 Jun; 13():77. PubMed ID: 23758906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling of tumor growth and anticancer effects of combination therapy.
    Koch G; Walz A; Lahu G; Schropp J
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):179-97. PubMed ID: 19387803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.